5FU/Oxaliplatin-Induced Jagged1 Cleavage Counteracts Apoptosis Induction in Colorectal Cancer: A Novel Mechanism of Intrinsic Drug Resistance.
5FU
CRC
GSIs
Jagged1
drug resistance
oxaliplatin
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
12
04
2022
accepted:
02
06
2022
entrez:
18
7
2022
pubmed:
19
7
2022
medline:
19
7
2022
Statut:
epublish
Résumé
Colorectal cancer (CRC) is characterized by early metastasis, resistance to anti-cancer therapy, and high mortality rate. Despite considerable progress in the development of new treatment options that improved survival benefits in patients with early-stage or advanced CRC, many patients relapse due to the activation of intrinsic or acquired chemoresistance mechanisms. Recently, we reported novel findings about the role of Jagged1 in CRC tumors with Kras signatures. We showed that Jagged1 is a novel proteolytic target of Kras signaling, which induces Jagged1 processing/activation resulting in Jag1-ICD release, which favors tumor development
Identifiants
pubmed: 35847908
doi: 10.3389/fonc.2022.918763
pmc: PMC9283835
doi:
Types de publication
Journal Article
Langues
eng
Pagination
918763Informations de copyright
Copyright © 2022 Pelullo, Zema, De Carolis, Cialfi, Giuli, Palermo, Capalbo, Giannini, Screpanti, Checquolo and Bellavia.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Leukemia. 2013 Feb;27(2):485-8
pubmed: 22846929
J Clin Oncol. 2000 Aug;18(16):2938-47
pubmed: 10944126
Expert Opin Ther Targets. 2018 Apr;22(4):331-342
pubmed: 29527929
Lancet. 2000 Mar 25;355(9209):1041-7
pubmed: 10744089
Ann Oncol. 2014 Dec;25(12):2378-2385
pubmed: 25294886
Clin Cancer Res. 2014 Jun 1;20(11):3033-43
pubmed: 24687927
Cell Cycle. 2014;13(13):2046-55
pubmed: 24801890
Int J Oncol. 2008 Dec;33(6):1223-9
pubmed: 19020755
Cancer Res. 2009 Aug 1;69(15):6065-73
pubmed: 19622776
Nat Rev Cancer. 2007 Aug;7(8):573-84
pubmed: 17625587
Cancer Res. 2019 Nov 1;79(21):5575-5586
pubmed: 31506332
Oncogenesis. 2020 Oct 18;9(10):93
pubmed: 33071287
Front Oncol. 2019 Apr 03;9:198
pubmed: 31001470
Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):16-27
pubmed: 26667886
Bioorg Med Chem Lett. 2015 Jan 15;25(2):192-7
pubmed: 25515559
Neoplasia. 2014 Dec;16(12):1007-17
pubmed: 25499214
Oncogenesis. 2018 May 25;7(5):42
pubmed: 29795369
Anticancer Res. 2013 Mar;33(3):1053-60
pubmed: 23482781
J Cancer. 2016 Jan 01;7(2):136-43
pubmed: 26819636
Cell Commun Signal. 2008 Oct 24;6:8
pubmed: 18950493
Eur J Cancer. 2012 May;48(7):997-1003
pubmed: 22445247
Apoptosis. 2013 Oct;18(10):1163-74
pubmed: 23887890
Signal Transduct Target Ther. 2020 Mar 20;5(1):22
pubmed: 32296018
Biomark Med. 2017 Sep;11(9):751-760
pubmed: 28747067
Exp Ther Med. 2021 Jun;21(6):585
pubmed: 33850557
Cell Death Dis. 2014 Apr 10;5:e1170
pubmed: 24722295
Clin Colorectal Cancer. 2008 May;7(3):206-11
pubmed: 18621641
Clin Colorectal Cancer. 2010 Oct;9(4):243-7
pubmed: 20920997
Proc Natl Acad Sci U S A. 2009 Apr 14;106(15):6315-20
pubmed: 19325125
J Clin Invest. 2013 Jul 1;:
pubmed: 23863623
Lancet Oncol. 2014 Jul;15(8):862-73
pubmed: 24928083
Cell Death Dis. 2017 Jul 20;8(7):e2942
pubmed: 28726779
World J Gastroenterol. 2017 Jul 14;23(26):4675-4688
pubmed: 28765689
Oncogene. 2010 Mar 11;29(10):1463-74
pubmed: 19966856
Cell Death Dis. 2018 Nov 26;9(12):1160
pubmed: 30478302
JAMA Oncol. 2016 May 01;2(5):643-653
pubmed: 26768652
Cancer Treat Rev. 2017 Sep;59:54-60
pubmed: 28738235